RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
For the Years Ended February 27, 2016, February 28, 2015 and March 1, 2014
(In thousands, except per share amounts)
2. Acquisition (Continued)
have a continuing impact on the consolidated results of operations. Specifically, these adjustments
reﬂect:
° Incremental interest expense relating to the $1,800,000 6.125% Notes issued on April 2, 2015,
the net proceeds of which were used finance the cash portion of the Acquisition.
° Incremental amortization resulting from increased fair value of the identifiable intangible assets
as noted in the preliminary purchase price allocation.
° Removal of costs incurred in connection with the Acquisition by both the Company and
EnvisionRX, including bridge loan commitment fees of $15,375.
0 Removal of interest expense incurred by EnvisionRX as the underlying debt was repaid upon the
acquisition date.
0 Removal of debt extinguishment charges incurred by EnvisionRX.
0 Inclusion of the 27,754 shares of Rite Aid common stock issued to fund the stock portion of the
purchase price in the basic and diluted share calculation.
The unaudited pro forma combined results do not include any incremental cost savings that may
result from the integration. The adjustments are based on information available to the Company at this
time. Accordingly, the adjustments are subject to change and the impact of such changes may be
material.
101